|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||4.4499 - 4.4499|
|52 Week Range||4.4499 - 6.8500|
|Beta (5Y Monthly)||0.63|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the company has successfully initiated the pivotal trial (OX124-002) for its lead pharmaceutical pipeline asset, OX124. The first cohort of healthy volunteers has been dosed on July 15, 2021.
"First commercial DTx contract signed with a large healthcare provider"
Sober Grid, the largest social media network for those in addiction recovery, and Orexo, a Swedish pharmaceutical company, today announced that Sober Grid's more than 300,000 users will gain access to Orexo's clinically proven digital therapeutics for problematic alcohol use (vorvida®) and depression (deprexis®) through their new partnership.